Research goals: Metabolic & Weight Description Retatrutide (development code LY3437943) is a synthetic, once-weekly triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors that has been the subject of peer-reviewed phase 1 and phase 2 randomized controlled trials published in The New England Journal of Medicine , The Lancet , and Nature Medicine , including investigations of body weight, glycemic control, and hepatic steatosis in adult human participants
From Medicaid data publicly available, there is no way yet to disentangle how much of the growing use of GLP-1s is related to treatment for diabetes, cardiovascular disease, or sleep apnea versus obesity, or a combination
Realworld weightloss effectiveness of glucagonlike peptide1 agonists among patients with type 2 diabetes: A retrospective cohort study
Altogether, the orexigenic and anabolic properties of ghrelin renders the ghrelin-GOAT-GHSR1a axis an attractive anti-obesity target
Br J Pharmacol 2016, 173(11): 1820-1834
